Company News for Mar 2, 2026

lunes, 2 de marzo de 2026, 10:34 am ET1 min de lectura
BCS--
CGON--
INTU--
XYZ--
  • Barclays PLC’s BCS shares declined 4% due to investor concern over the bank’s exposure to the collapse of U.K.-based mortgage lender Market Financial Solutions, fueling broader financial-sector weakness.
  • Shares of BlockXYZ--, Inc. XYZ soared 16.8% after the company unveiled sweeping job cuts aimed at boosting efficiency through greater AI adoption.
  • Shares of Intuit Inc.INTU-- INTU gained 3.7% after it reported second-quarter fiscal 2026 revenues of $4.65 billion, beating the Zacks Consensus Estimate of $4.53 billion.
  • CG Oncology, Inc.’s CGON shares jumped 4.8% after it reported fourth-quarter 2025 losses of 51 cents per share, narrower than the Zacks Consensus Estimate of a loss of 61 cents.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include

Stock #1: A Disruptive Force with Notable Growth and Resilience

Stock #2: Bullish Signs Signaling to Buy the Dip

Stock #3: One of the Most Compelling Investments in the Market

Stock #4: Leader In a Red-Hot Industry Poised for Growth

Stock #5: Modern Omni-Channel Platform Coiled to Spring

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.

See Our Newest 5 Stocks Set to Double Picks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report



Barclays PLC (BCS): Free Stock Analysis Report

Intuit Inc. (INTU): Free Stock Analysis Report

CG Oncology, Inc. (CGON): Free Stock Analysis Report

Block, Inc. (XYZ): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios